×
About 1,238 results

ALLMedicine™ Sudden Unexpected Death In Epilepsy Center

Research & Reviews  427 results

Confirmation of Cause of Death Via Comprehensive Autopsy and Whole Exome Molecular Sequ...
https://doi.org/10.1161/JAHA.121.021170
Journal of the American Heart Association; Chahal CAA, Tester DJ et. al.

Nov 25th, 2021 - Background Sudden cardiac arrest is the leading mode of death in the United States. Epilepsy affects 1% of Americans; yet epidemiological data show a prevalence of 4% in cases of sudden cardiac arrest. Sudden unexpected death in epilepsy (SUDEP) m...

Challenges in Decoding Sudden Unexpected Death in Epilepsy: The Intersection Between He...
https://doi.org/10.1161/JAHA.121.023571
Journal of the American Heart Association; Asatryan B

Nov 25th, 2021 - Challenges in Decoding Sudden Unexpected Death in Epilepsy: The Intersection Between Heart and Brain in Epilepsy.|2021|Asatryan B,|

Interictal autonomic changes in persons with epilepsy (PWE) on carbamazepine (CBZ) vers...
https://doi.org/10.1016/j.yebeh.2021.108396
Epilepsy & Behavior : E&B; Jain S, Nair PP et. al.

Nov 18th, 2021 - Epilepsy is one of the most prevalent neurological conditions and carbamazepine is a commonly used anti-seizure drug (ASD), especially in developing nations. There are reports of carbamazepine causing atrioventricular conduction defects and autono...

SUDEP risk and autonomic dysfunction in genetic epilepsies.
https://doi.org/10.1016/j.autneu.2021.102907
Autonomic Neuroscience : Basic & Clinical; Sahly AN, Shevell M et. al.

Nov 14th, 2021 - The underlying pathophysiology of sudden unexpected death in epilepsy (SUDEP) remains unclear. This phenomenon is likely multifactorial, and there is considerable evidence that genetic factors play a role. There are certain genetic causes of epile...

Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet sy...
https://doi.org/10.1016/j.seizure.2021.10.024
Seizure Cross JH, Galer BS et. al.

Nov 13th, 2021 - To assess the impact of fenfluramine (FFA) on the expected mortality incidence, including sudden unexpected death in epilepsy (SUDEP), in persons with Dravet syndrome (DS). In this pooled analysis, total time of exposure for persons with DS who we...

see more →

Guidelines  1 results

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and ris...
https://doi.org/10.1212/WNL.0000000000003685
Neurology Harden C, Tomson T et. al.

Apr 26th, 2017 - To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in different epilepsy populations and address the question of whether risk factors for SUDEP have been identified. Systematic review of evidence; modified Grading Reco...

see more →

Clinicaltrials.gov  4 results

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
https://clinicaltrials.gov/ct2/show/NCT02929667

May 4th, 2020 - Sudden unexpected death in epilepsy (SUDEP) refers to the sudden, unexpected, nontraumatic, non-drowning, witnessed or unwitnessed death of an individual with epilepsy. Postmortem examination in such cases fails to reveal an obvious medical or tox...

Cardiac Arrhythmias in Dravet Syndrome
https://clinicaltrials.gov/ct2/show/NCT02415686

Sep 7th, 2018 - SUMMARY Rationale: People with Dravet Syndrome (DS), a rare epilepsy syndrome, have a high risk of Sudden Unexpected Death in Epilepsy (SUDEP). Mouse models indicated that the responsible sodium channel mutation (SCN1A) not only alters cortical ex...

Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures
https://clinicaltrials.gov/ct2/show/NCT02469844

Apr 9th, 2018 - Epilepsy is disabling and costly to patients and the health service. Nearly 400,000 people in England suffer from epilepsy. About 40% of these patients are known to have seizures predominantly in sleep. All seizures pose risk to the individual bot...

Efficacy of Fluoxetine Against Seizure-induced Central Apneas
https://clinicaltrials.gov/ct2/show/NCT02569970

Oct 5th, 2016 - Sudden unexpected death in epilepsy (SUDEP) is a tragic outcome of seizure disorders that primarily affect young adults suffering from refractory epilepsy. In this population, SUDEP incidence is estimated at 0.5%. While the mechanisms of SUDEP are...

see more →

News  63 results

CPET in COVID Long-Haulers; Omicron Suspected at Conference; Aspirin a No-No in HF?
https://www.medpagetoday.com/cardiology/prevention/95932

Nov 30th, 2021 - Exercise-induced premature ventricular contractions occurring during recovery were bad news for asymptomatic people. (Journal of the American College of Cardiology) Cardiopulmonary exercise testing (CPET) revealed that some COVID-19 long-haulers w...

Deeper Sleep, Slower Heart Rate Tied to Sudden Death in Epilepsy
https://www.medscape.com/viewarticle/951137

May 14th, 2021 - Deeper sleep and slower heart rate following seizures may work synergistically to increase the risk for sudden unexpected death in epilepsy (SUDEP), new research suggests. Investigators analyzed data on 100 seizures in 42 patients with epilepsy. T...

COVID-19's Global Impact on Epilepsy
https://www.medscape.com/viewarticle/943001

Dec 21st, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Around the globe, the COVID-19 pandemic has placed an enormous strain on patients with epilepsy, new research shows. The pandemic also appears to ...

SUDEP May Explain 3% of All Sudden Deaths in Kids
https://www.medscape.com/viewarticle/942139

Dec 7th, 2020 - Sudden unexpected death in epilepsy (SUDEP) may explain 3% of all sudden deaths in children – a prevalence rate that is at least three times greater than previously reported estimates – new research shows Dr Vicky Whittemore Just a few years ago, ...

FDA Okays New Treatment for Dravet Syndrome
https://www.medscape.com/viewarticle/933039

Jun 26th, 2020 - The US Food and Drug Administration (FDA) has approved fenfluramine (Fintepla, Zogenix) oral solution, a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in children age 2 years and older. Dravet synd...

see more →